SEC Tracker
Get the app

Recursion Pharmaceuticals RXRX

Recursion Pharmaceuticals Q2 FY24: revenue $14.4M; diluted EPS −$0.40

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Recursion Pharmaceuticals reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$14.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$97.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.40No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$474.3MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$82.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Recursion Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
  2. Vericel VCEL public float $2.1B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  5. Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025